Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

VREX vs MPTI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VREX Captures Overall Composite Edge (54.8 HOLD vs 37.1 SELL), While MPTI Leads 3–2 on Growth & Valuation Pillars

VREX Overall Winner 6-Pillar Tally: VREX 2 – 3 MPTI (1 Tie) Matrix Metrics: VREX 5 – 5 MPTI

As of Nov 20, 2026, Varex Imaging Corporation (VREX) captures the overall head-to-head institutional edge over M-tron Industries, Inc. (MPTI) on higher Unified Composite conviction (54.8/100 HOLD vs. 37.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while MPTI wins 3–2 across the 6-pillar growth and valuation breakdown. VREX trades at $18.10 (16.9x Forward P/E, 8.3% operating margin) versus MPTI at $63.24 (19.8x Forward P/E, 17.8% operating margin).

  • Growth vs. Quality Trade-Off: VREX earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. MPTI 37.1/100 SELL) and 0.65β · 5% Vol risk profile, whereas MPTI leads top-line expansion (+11.1% YoY revenue growth, 1.05x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4); meanwhile MPTI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VREX vs MPTI
VREX NASDAQ Head-to-Head Winner
Varex Imaging Corporation Common Stock
Electronic Components, Nec
$18.10
-0.22% 1D
Market Cap $770.3M
TTM Revenue $865M
Forward P/E 16.9x
Beta / 30D Vol 0.65β · 5% Vol
Unified Composite Score
54.8 / 100 HOLD
Tech 46.0 Fund 45.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.3%) with fading momentum, RSI 28
RSI-14: 28.4 · SMA20: $18.34 · SMA50: $18.41
MPTI NYSE American
M-tron Industries, Inc.
Electronic Components, Nec
$63.24
-4.24% 1D
Market Cap $287.0M
TTM Revenue $60M
Forward P/E 19.8x
Beta / 30D Vol 1.67β · 64% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 21.0 Fund 49.0 Flow 50.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.5%), weak momentum, RSI 44
RSI-14: 44.0 · SMA20: $65.17 · SMA50: $69.61

6-Pillar Scorecard Institutional Category Breakdown (VREX 2 – 3 MPTI)

Columns: Metric · VREX · MPTI
1. Valuation Multiples VREX
Forward P/E 16.9x 19.8x
Trailing P/E 34.2x 24.8x
PEG Ratio 6.30x 1.05x
EV / Revenue 0.9x 3.9x
2. Growth & Scale VREX
Revenue Growth (YoY) +3.7% +11.1%
Earnings Growth (YoY) +453.4% +16.7%
TTM Revenue (USD) $865M $60M
Market Cap $770.3M $287.0M
3. Profitability & Quality MPTI
Gross Margin 34.3% 44.3%
Operating Margin 8.3% 17.8%
Net Profit Margin 2.6% 18.0%
Return on Equity (ROE) 4.6% 13.5%
4. Balance Sheet & Cash Flow MPTI
Cash Generation (TTM) $100M EBITDA $8.8M
Cash Flow Margin 11.5% EBITDA Mgn 14.6%
Net Cash / Leverage $11.78 Book/Sh · 4.6% ROE $52M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 112.0% (18th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MPTI
OpEx & R&D Intensity 26.0% of Rev ($225M) 26.5% of Rev ($16M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Medical Devices Operator Electronic Components Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VREX (5) vs MPTI (5)
Institutional Metric VREX MPTI Criterion Row Edge
Market Capitalization
Scale
$770.3M $287.0M Larger Scale VREX
Trailing P/E Ratio
Valuation
34.2x 24.8x Lower Multiple MPTI
Forward P/E Ratio
Valuation
16.9x 19.8x Lower Multiple VREX
Revenue Growth (YoY)
Growth
+3.7% +11.1% Higher Growth MPTI
Operating Margin (TTM)
Profitability
8.3% 17.8% Higher Margin MPTI
Net Profit Margin
Profitability
2.6% 18.0% Higher Margin MPTI
Return on Equity (ROE)
Capital Efficiency
4.6% 13.5% Higher ROE MPTI
52-Week Range Position
Momentum
94% ($9–$19) 32% ($44–$105) Stronger Trend VREX
Beta / 30D Volatility
Risk Regime
0.65β · 5% Vol 1.67β · 64% Vol Lower Realized Risk VREX
Unified Institutional Score
Composite Signal
54.8 / 100 (HOLD) 37.1 / 100 (SELL) Higher Composite VREX
Trailing 12M Revenue (USD)
Operating Scale
$865M $60M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
34.3% 44.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
6.30x PEG · 0.9x EV/Rev 1.05x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$100M EBITDA ($11.78 Book/Sh · 4.6% ROE) $8.8M ($52M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VREX +2.12 pp
VREX: -1.68% · MPTI: -3.8%
3M Horizon VREX +17.72 pp
VREX: -2.27% · MPTI: -19.99%
6M Horizon VREX +103.55 pp
VREX: +79.74% · MPTI: -23.81%
1Y Horizon VREX +39.28 pp
VREX: +76.76% · MPTI: +37.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VREX vs MPTI. Trailing 12-month operating profitability (VREX 8.3% vs MPTI 17.8%) and valuation multiples (VREX 16.9x vs MPTI 19.8x Forward P/E) are benchmarked directly in Pillar 4 below.

VREX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$865M
Gross Margin34.3%
Op. Margin8.3%
ROE / Fwd P/E4.6% · 16.9x
MPTI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$60M
Gross Margin44.3%
Op. Margin17.8%
ROE / Fwd P/E13.5% · 19.8x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VREX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 112.0%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VREX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MPTI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MPTI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VREX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $770.3M market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 26.0% of Rev ($225M)
90D Engineering Disclosures 0 Published
MPTI Moat Profile Scale & Operating Efficiency Moat
Electronic Components Operator
Competes within the Electronic Components value chain with $287.0M market capitalization and 17.8% operating margin.
OpEx & R&D Reinvestment 26.5% of Rev ($16M)
90D Engineering Disclosures 0 Published

Investor FAQ VREX vs MPTI Key Questions & Quantitative Answers

As of Nov 20, 2026, Varex Imaging Corporation (VREX) captures the overall head-to-head institutional edge over M-tron Industries, Inc. (MPTI) on higher Unified Composite conviction (54.8/100 HOLD vs. 37.1/100 SELL) after splitting the core matrix 5–5 (led by Valuation Multiples, Growth & Scale), while MPTI wins 3–2 across the 6-pillar growth and valuation breakdown. VREX trades at $18.10 (16.9x Forward P/E, 8.3% operating margin) versus MPTI at $63.24 (19.8x Forward P/E, 17.8% operating margin). Growth vs. Quality Trade-Off: VREX earns the overall head-to-head edge with a stronger Unified Composite Score (54.8/100 HOLD vs. MPTI 37.1/100 SELL) and 0.65β · 5% Vol risk profile, whereas MPTI leads top-line expansion (+11.1% YoY revenue growth, 1.05x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: VREX is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 28.4); meanwhile MPTI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 44.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VREX leads the Growth & Scale pillar: VREX posts +3.7% YoY revenue growth and +453.4% YoY earnings growth on $865M TTM revenue (34.3% gross margin, 8.3% operating margin), compared with MPTI at +11.1% YoY revenue growth and +16.7% YoY earnings growth on $60M TTM revenue (44.3% gross margin, 17.8% operating margin). On trailing 12-month operating scale, VREX generates $865M in USD-normalized revenue versus $60M for MPTI. In operating R&D and SG&A reinvestment, VREX deploys 26.0% of Rev ($225M) (0 90-day corporate R&D disclosures) versus 26.5% of Rev ($16M) (0 disclosures) for MPTI.

VREX screens cheaper on headline valuation multiples. VREX trades at 16.9x Forward P/E, 34.2x Trailing P/E, 6.30x PEG, and 0.9x EV/Revenue (11.5% EBITDA margin), whereas MPTI trades at 19.8x Forward P/E, 24.8x Trailing P/E, 1.05x PEG, and 3.9x EV/Revenue (14.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VREX (4.6% ROE) versus MPTI (13.5% ROE) capital efficiency.

In options market volatility and institutional positioning, VREX carries 112.0% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 5% Vol realized risk). By comparison, MPTI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.67β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.